Actavis now markets over 120 hospital products, a number that is rising rapidly, with around 650 applications pending worldwide for injectable medicines.
In addition is an ambitious development pipeline with around 250 further new hospitals applications expected to be submitted during 2010/11.
In addition to oncology medicines, Actavis also markets a growing range of anti-infectives, local anaesthetics and analgesics.
Actavis’ hospital portfolio includes a comprehensive oncology range comprising over 30 molecules. These products are currently sold in markets all over the globe including the EU, US and Japan.
In addition to it’s own label pharmaceuticals, Actavis produces a range of oncology and non oncology injectable products for a range of commercial clients. These include branded companies such Pfizer and many of the leading generic houses, thus allowing other companies to take advantage of our manufacturing pedigree and scale.
You may already be using Actavis produced products without even knowing it.
Safe, reliable products
Actavis offers fast access to a wide choice of pharmaceuticals. We operate contemporary GMP-approved manufacturing facilities in Europe, with meticulous in-house quality standards and rigorous regulatory environments ensuring the highest quality at all times.
This quality is reflected in our commercial customer base, which includes a number of leading businesses such as Pfizer and leading generic players such as Teva and Sandoz.
Actavis produces in excess of eight million vials for oncology treatments each year, providing freeze-dried and solution products, as well as high volumes of cytotoxic and non-cytotoxic injectables, for sale primarily across Europe, the US and Japan.a
Supply on demand
Actavis has a robust supply chain that is more flexible than many of our competitors’.
We hold bulk supplies of undifferentiated, near-finished goods which can then be finalised quickly and efficiently for different markets – especially reassuring for anyone who has
experienced stock-out situations.
As a relative newcomer to the field of hospital medicines, we have had the advantage of being able to design an appropriate supply chain from scratch, unlike more mature incumbents. Reduced lead times, enhanced flexibility and improved customer service are among the factors contributing to the growth of Actavis in the hospital sector.
Active protection
Actavis is targeting the safety of clinicians and patients in a variety of ways, all of which play important roles in reducing error and wastage, whilst increasing efficiency.
Caring for the environment
Actavis is committed to protecting the environment and this is demonstrated by tangible actions not just words.
Download brochure (PDF, 285kb)